Capital Management Corp VA Increases Position in Exelixis, Inc. (NASDAQ:EXEL)

Capital Management Corp VA increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 7.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 365,270 shares of the biotechnology company’s stock after acquiring an additional 25,350 shares during the quarter. Exelixis makes up 1.7% of Capital Management Corp VA’s portfolio, making the stock its 26th biggest position. Capital Management Corp VA owned 0.13% of Exelixis worth $9,479,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. LSV Asset Management increased its holdings in Exelixis by 107.7% in the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after buying an additional 2,989,021 shares during the last quarter. Jupiter Asset Management Ltd. raised its position in shares of Exelixis by 148.2% during the 1st quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock valued at $53,817,000 after acquiring an additional 1,354,062 shares in the last quarter. Swedbank AB bought a new position in Exelixis during the first quarter worth $22,455,000. Susquehanna Fundamental Investments LLC acquired a new position in Exelixis in the first quarter worth $10,906,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the sale, the executive vice president now directly owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $28.39, for a total value of $709,750.00. Following the completion of the transaction, the executive vice president now owns 580,325 shares of the company’s stock, valued at $16,475,426.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the transaction, the executive vice president now owns 520,990 shares of the company’s stock, valued at $13,024,750. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 354,020 shares of company stock valued at $9,386,366 over the last 90 days. 2.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. UBS Group assumed coverage on Exelixis in a research report on Thursday, September 19th. They set a “neutral” rating and a $30.00 price objective for the company. Oppenheimer restated an “outperform” rating and issued a $29.00 price target on shares of Exelixis in a research note on Tuesday, July 30th. HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, September 18th. JMP Securities restated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research report on Friday, October 11th. Finally, Bank of America boosted their price target on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.44.

Exelixis Trading Up 0.5 %

EXEL opened at $34.29 on Tuesday. The stock has a fifty day moving average price of $27.13 and a 200 day moving average price of $24.31. Exelixis, Inc. has a 1 year low of $19.20 and a 1 year high of $34.65. The stock has a market cap of $9.79 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 0.92 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. The business had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. As a group, sell-side analysts forecast that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.